var data={"title":"Tacrolimus (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tacrolimus (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390450?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tacrolimus-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tacrolimus (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=tacrolimus-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tacrolimus (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559505\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancies and serious infection:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Increased susceptibility to bacterial, viral, fungal, and protozoal infections, including opportunistic infections and the possible development of malignancies such as lymphoma and skin cancer may result from immunosuppression and may lead to hospitalization or death.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\"> Only health care providers experienced in immunosuppressive therapy and management of organ transplant patients should prescribe tacrolimus. Manage patients receiving the drug in facilities equipped and staffed with adequate laboratory and supportive medical resources. The health care provider responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mortality in liver transplantation (Astagraf XL):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Increased mortality in female transplant patients with Astagraf XL. Astagraf XL is not approved for use in liver transplantation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559510\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Astagraf XL;</li>\n      <li>Envarsus XR;</li>\n      <li>Hecoria [DSC];</li>\n      <li>Prograf</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559511\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Advagraf;</li>\n      <li>Prograf</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564525\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Calcineurin Inhibitor;</li>\n      <li>\n        Immunosuppressant Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564218\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Hecoria has been discontinued in the US for more than 1 year. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immunosuppression after solid-organ transplant, sublingual administration: </b>Sublingual (off-label route): Immediate release: Optimal dosing has not been determined. In dosing regimens using sublingual administration of the contents of immediate release tacrolimus capsules, the sublingual to oral dosing ratio has ranged from 1:3 to 1:1 (Collin 2010; Nasiri-Toosi 2012). However, most studies suggest a dosing ratio of 1:2 (or 50% of the oral dose given sublingually), and most centers use this approach in practice (Doligalski 2014; Watkins 2012). Adjust dose based on serum trough concentrations. Lower doses of sublingual tacrolimus may be required during coadministration of drugs that inhibit tacrolimus metabolism (Collin 2010; Reams 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of organ rejection in transplant recipients: Note:</b> While recommendations for initial doses exist, drug interactions should be considered. After initial dose, titrate to achieve target trough concentrations. Adjunctive therapy with other immunosuppressants including but not limited to corticosteroids is recommended early post-transplant. IV route should only be used in patients not able to take oral medications and continued only until oral medication can be tolerated; anaphylaxis has been reported with IV administration. If switching from IV to oral, the oral dose should be started 8 to 12 hours after stopping the infusion. Sublingual administration should be considered in those unable to take oral.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Liver transplant:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Initial: 0.1 to 0.15 mg/kg/day in 2 divided doses, given every 12 hours (titrate to target trough concentrations), consider lower dose in liver transplant recipients with graft dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: 0.1 to 0.2 mg/kg once daily in combination with corticosteroids; initiate within 12 to 18 hours of transplantation; titrate to target trough concentrations (Advagraf Canadian product labeling 2015). <b>Note:</b> In the US, Astagraf XL is not approved for use in liver transplantation due to an increase in mortality in female liver transplant recipients receiving Astagraf XL.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from immediate release to extended release (Advagraf [Canadian product])</i>: Patients stable on immediate release tacrolimus may be converted to extended release by initiating extended-release treatment in a 1:1 ratio (mg:mg) using previously established total daily dose of immediate-release product. Administer once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 0.03 to 0.05 mg/kg/day as a continuous infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart transplant:</b> Use in combination with an antimetabolite agent (eg, azathioprine or mycophenolate mofetil) is recommended. Instead of an antimetabolite, may also use in combination with an mTOR kinase inhibitor (eg, everolimus, sirolimus) (Fuchs 2014; Guethoff 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release: Initial: 0.075 mg/kg/day in 2 divided doses, given every 12 hours (titrate to target trough concentrations)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 0.01 mg/kg/day as a continuous infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from oral to continuous IV infusion:</i> According to the ISHLT guidelines for the care of heart transplant recipients, convert from oral to IV by administering one-fifth (1/5th) of the oral daily dose as a continuous infusion over 24 hours (ISHLT [Costanzo 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Kidney transplant:</b> Use in combination with azathioprine or mycophenolate mofetil is recommended. <b>Note:</b> African-American patients may require larger doses to attain trough concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release (Hecoria, Prograf): Initial: 0.2 mg/kg/day in combination with azathioprine or 0.1 mg/kg/day in combination with mycophenolate mofetil; titrate to target trough concentrations. Administer in 2 divided doses, given every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from immediate release oral to IV:</i> Administer one-third (1/3rd) of the oral dose as a continuous infusion over 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release (Advagraf [Canadian product], Astagraf XL):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">With basiliximab induction (prior to reperfusion or within 48 hours of transplant completion): 0.15 to 0.2 mg/kg once daily (in combination with corticosteroids and mycophenolate); titrate to target trough concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Without basiliximab induction: Preoperative dose (administer within 12 hours prior to reperfusion): 0.1 mg/kg (in combination with corticosteroids and mycophenolate)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Without basiliximab induction: Postoperative dosing (administer at least 4 hours after preoperative dose and within 12 hours of reperfusion): 0.2 mg/kg once daily (in combination with corticosteroids and mycophenolate); titrate to target trough concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from IV to extended release</i> (<i>Astagraf XL, Envarsus XR</i>): Administer the first oral extended release dose 8 to 12 hours after discontinuation of IV tacrolimus</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from immediate release to extended release</i> (<i>Advagraf</i> [<i>Canadian product</i>], <i>Astagraf XL</i>): Initiate extended release treatment in a 1:1 ratio (mg:mg) using previously established total daily dose of immediate release (Advagraf Canadian product labeling 2015; Van Hooff 2012). Administer once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from immediate release to extended release</i> (<i>Envarsus XR</i>): Initiate extended-release treatment with a once-daily dose that is 70% to 80% of the total daily dose of the immediate-release tacrolimus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 0.03 to 0.05 mg/kg/day as a continuous infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Graft-versus-host disease (GVHD) (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prevention:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Convert from IV to immediate release oral dose (1:4 ratio): Multiply total daily IV dose times 4 and administer in 2 divided oral doses per day, every 12 hours (Uberti 1999; Yanik 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 0.03 mg/kg/day (based on lean body weight) as continuous infusion. Treatment should begin at least 24 hours prior to stem cell infusion and continued only until oral medication can be tolerated (Przepiorka 1999; Yanik 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate release: 0.06 mg/kg twice daily (Furlong 2000; Przepiorka 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 0.03 mg/kg/day (based on lean body weight) as continuous infusion (Furlong 2000; Przepiorka 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lung transplant (off-label use):</b> Usually used in a combination regimen that contains a corticosteroid and either azathioprine or mycophenolate (Snell 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral, nasogastric: Immediate release: 0.05 to 0.3 mg/kg/day in 2 divided doses, given every 12 hours (usual dose: 0.05 mg/kg every 12 hours); titrate to target trough concentrations (Treede 2001; Treede 2012; Zuckermann 2003). May also be administered sublingually at ~50% of the oral/NG dose (Doligalski 2014; Watkins 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> May convert from twice-daily dosing to once-daily dosing (on a mg per mg basis) using the extended-release formulation (Astagraf XL [US] or Advagraf [Canada]) in stable lung transplant recipients (Mendez 2014). May convert to extended-release Envarsus with a once-daily dose that is 70% to 80% of the total daily dose of immediate-release tacrolimus although clinical trial data is lacking.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.01 to 0.05 mg/kg over 24 hours as a continuous IV infusion; titrate to target trough concentrations (Treede 2001; Treede 2012; Zuckermann 2003). For patients receiving the initial dose of tacrolimus intravenously, may begin immediately after transplantation, or up to 2 days postoperatively depending on renal function and hemodynamic stability (Treede 2001; Treede 2012; Witt 2013; Zuckermann 2003). When patient is able to take oral medication, may switch to an oral maintenance regimen (typically transitioned after extubation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis</b> <b>(refractory) (off-label use):</b> Oral: Immediate release: 2 to 3 mg once daily in combination with NSAID and/or oral corticosteroid therapy; 3 mg once daily resulted in better ACR response rates (Yocum 2003). In patients not responsive to methotrexate alone, may add tacrolimus at a lower dose (ie, 1.5 mg once daily) in combination with methotrexate (Lee 2016). Carefully monitor serum creatinine during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564217\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=tacrolimus-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tacrolimus (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Hecoria has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Liver transplant:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate release: Initial: 0.15 to 0.20 mg/kg/day in 2 divided doses, given every 12 hours (titrate to target trough concentrations)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 0.03 to 0.05 mg/kg/day as a continuous infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The initial postoperative dose of tacrolimus should begin no sooner than 6 hours after liver and heart transplant and within 24 hours of kidney transplant (but may be delayed until renal function has recovered). Adjunctive therapy with corticosteroids is recommended early post-transplant. IV route should only be used in patients not able to take oral medications and continued only until oral medication can be tolerated; anaphylaxis has been reported with IV administration. If switching from IV to oral, the oral dose should be started 8-12 hours after stopping the infusion. Patients without pre-existing renal or hepatic dysfunction have required (and tolerated) higher doses than adults to achieve similar blood concentrations. It is recommended that therapy be initiated at the <b>high end</b> of the recommended adult IV and oral dosing ranges; dosage adjustments may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of graft-vs-host disease (GVHD) (off-label use):</b> Oral, IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564219\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution; begin at the low end of dosing range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564220\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Renal impairment does not affect the elimination or serum concentrations of tacrolimus; however, tacrolimus may cause nephrotoxicity requiring dose reduction. Evidence suggests that lower doses should be used; patients should receive doses at the lowest amount of the recommended IV and oral dosing ranges; further reductions in dose below these ranges may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not removed by hemodialysis; supplemental dose is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: Significant drug removal is unlikely based on physiochemical characteristics.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564221\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use of tacrolimus in liver transplant recipients experiencing post-transplant hepatic impairment may be associated with increased risk of developing renal insufficiency related to high whole blood levels of tacrolimus. The presence of moderate-to-severe hepatic dysfunction (serum bilirubin &gt;2 mg/dL; Child-Pugh score &ge;10) appears to affect the metabolism of tacrolimus. The half-life of the drug was prolonged and the clearance reduced after IV administration. The bioavailability of tacrolimus was also increased after oral administration. The higher plasma concentrations as determined by ELISA, in patients with severe hepatic dysfunction are probably due to the accumulation of metabolites of lower activity. These patients should be monitored closely and dosage adjustments should be considered. Some evidence indicates that lower doses could be used in these patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564277\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hecoria: 0.5 mg [DSC], 1 mg [DSC], 5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prograf: 0.5 mg, 1 mg, 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg, 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Astagraf XL: 0.5 mg, 1 mg, 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prograf: 5 mg/mL (1 mL) [contains alcohol, usp, cremophor el]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Envarsus XR: 0.75 mg, 1 mg, 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559517\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29038337\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Prograf injection contains polyoxyl 60 hydrogenated castor oil (HCO-60)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13262301\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule Extended Release 24 Hour, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advagraf: 0.5 mg, 1 mg, 3 mg, 5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50136484\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Hecoria has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099222\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Astagraf XL: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362199.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WslJQR48rpG4rf8i2Z0emrw==&amp;TOPIC_ID=9920\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362199.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564223\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: If IV administration is necessary, administer by continuous infusion (generally, over 24 hours). Do not use PVC tubing when administering diluted solutions. Do not mix with solutions with a pH &ge;9 (eg, acyclovir or ganciclovir) due to chemical degradation of tacrolimus (use different ports in multilumen lines). Do not alter dose with concurrent T-tube clamping. Adsorption of the drug to PVC tubing may become clinically significant with low concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Administer with or without food; be consistent with timing and composition of meals if GI intolerance occurs and administration with food becomes necessary (per manufacturer). If dosed once daily, administer in the morning. If dosed twice daily, doses should be 12 hours apart. If the morning and evening doses differ, the larger dose (differences are never &gt;0.5 to 1 mg) should be given in the morning. Some data suggests that the larger dose should be given in the evening since tacrolimus exposure may be reduced in the evening (Iwahori 2005; Min 1997; Park 2007). If dosed 3 times daily, separate doses by 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Combination therapy with everolimus for liver transplantation: Administer tacrolimus at the same time as everolimus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: For all US preparations, administer on an empty stomach at least 1 hour before or 2 hours after a meal. Advagraf [Canadian product] labeling suggests that the capsule may be taken with food if necessary but should be administered consistently with or without food. Swallow whole, do not chew, crush, or divide. Take once daily in the morning at a consistent time each day. Missed doses may be taken up to 14 hours (15 hours for Envarsus XR) after scheduled time; if &gt;14 hours (&gt;15 hours for Envarsus XR), resume at next regularly scheduled time; do not double a dose to make up for a missed dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasogastric tube: If unable to swallow capsules, contents of immediate release capsule(s) may be mixed with water and flushed through a nasogastric tube; clamp nasogastric tube for 30 to 60 minutes after administration (Taylor 2001). <b>Note:</b> Dosing for immediate release capsules is not equivalent to dosing of Envarsus XR. When switching from Envarsus XR to immediate release capsules for nasogastric administration, consider administering a 20% to 30% higher total daily dose of immediate release tacrolimus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual: If unable to swallow capsules, tacrolimus may be administered sublingually (at a reduced dose) by opening the immediate-release capsules and placing the contents of the capsule(s) under the tongue, allowing contents to completely dissolve. The patient should avoid swallowing for 5 to 15 minutes and avoid oral intake for 15 to 30 minutes; also avoid mechanical suctioning for at least 30 minutes after administration (Doligalski 2014; Pennington 2015; Watkins 2012). <b>Note:</b> Absorption of a single dose of tacrolimus suspension given by the sublingual route was inadequate. (Snell 2013b)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133425\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving, a gown, and (if dosage form allows) CSTDs are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559518\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Organ rejection prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Astagraf XL: Prevention of organ rejection in kidney transplant recipients in combination with other immunosuppressants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Envarsus XR: Prevention of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulation, in combination with other immunosuppressants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hecoria and Prograf: Prevention of organ rejection in heart, kidney, and liver transplant recipients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Extended-release products (Astagraf XL and Envarsus XR) are not interchangeable or substitutable with immediate release tacrolimus. In addition, the once-daily formulations (Astagraf XL and Envarsus XR) are not interchangeable with each other due to significantly different pharmacokinetic properties.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744916\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Graft-versus-host disease (prevention/treatment); Immunosuppression (maintenance) after lung transplant; Intestinal transplant; Rheumatoid arthritis (refractory); Uveitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559508\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Prograf may be confused with Gengraf, PROzac</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tacrolimus may be confused with everolimus, pimecrolimus, sirolimus, tamsulosin, temsirolimus</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The immediate release (Hecoria, Prograf) and extended release (Astagraf XL, Advagraf [Canadian product]) oral formulations are not interchangeable and are not substitutable.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559542\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris, atrial fibrillation, atrial flutter, bradycardia, cardiac arrhythmia, cardiac failure, cerebral infarction, cerebral ischemia, chest pain, deep vein thrombophlebitis, deep vein thrombosis, ECG abnormality (QRS or ST segment or T wave), edema, flushing, hemorrhagic stroke, hypertension, hypertrophic cardiomyopathy, hypotension, ischemic heart disease, localized phlebitis, myocardial infarction, orthostatic hypotension, pericardial effusion, peripheral edema, peripheral vascular disease, phlebitis, syncope, tachycardia, thrombosis, vasodilatation, ventricular premature contractions</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal dreams, abnormality in thinking, agitation, amnesia, anxiety, aphasia, ataxia, brain disease, carpal tunnel syndrome, chills, confusion, depression, dizziness, drowsiness, emotional lability, excessive crying, falling, fatigue, flaccid paralysis, hallucination, headache, hypertonia, hypoesthesia, insomnia, mental status changes, mood elevation, myasthenia, myoclonus, nervousness, neuropathy (including compression), neurotoxicity, nightmares, pain, paresis, paresthesia, peripheral neuropathy, psychosis, seizure, vertigo, voice disorder, writing difficulty</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris, alopecia, cellulitis, condyloma acuminatum, dermal ulcer, dermatitis (including fungal), dermatological reaction, diaphoresis, exfoliative dermatitis, pruritus, skin discoloration, skin photosensitivity, skin rash, tinea versicolor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Acidosis, albuminuria, alkalosis, anasarca, Cushing's syndrome, decreased serum bicarbonate, decreased serum iron, dehydration, diabetes mellitus, gout, hirsutism, hypercalcemia, hypercholesterolemia, hyperkalemia, hyperphosphatemia, hypertriglyceridemia, hypervolemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, increased gamma-glutamyl transferase, increased lactate dehydrogenase, weight changes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, anorexia, dyspepsia, aphthous stomatitis, cholangitis, colitis, constipation, delayed gastric emptying, diarrhea, duodenitis, dysphagia, enlargement of abdomen, esophagitis (including ulcerative), flatulence, gastric ulcer, gastritis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gastrointestinal perforation, hernia, hiccups, increased appetite, intestinal obstruction, nausea, oral candidiasis, pancreatic disease (pseudocyst), pancreatitis (including hemorrhagic and necrotizing), peritonitis, rectal disease, stomach cramps, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Anuria, bladder spasm, cystitis, dysuria, hematuria, nocturia, oliguria, proteinuria, toxic nephrosis, urinary frequency, urinary incontinence, urinary retention, urinary tract infection, urinary urgency, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, blood coagulation disorder, bruise, decreased prothrombin time, hemolytic anemia, hemorrhage, hypochromic anemia, hypoproteinemia, increased hematocrit, increased INR, Kaposi&rsquo;s sarcoma, leukocytosis, leukopenia, malignant neoplasm of bladder, malignant neoplasm of thyroid (papillary), neutropenia, pancytopenia, polycythemia, skin neoplasm, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests, ascites, cholestatic jaundice, hepatic injury, hepatitis (including acute, chronic, and granulomatous), hyperbilirubinemia, increased serum alkaline phosphatase, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Graft complications</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess, infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain, leg cramps, muscle spasm, muscle weakness of the extremities, myalgia, osteoporosis, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Amblyopia, blurred vision, conjunctivitis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Hearing loss, otalgia, otitis externa, otitis media, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure, hydronephrosis, increased blood urea nitrogen, increased serum creatinine, renal disease (BK nephropathy), renal function abnormality, renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Allergic rhinitis, asthma, atelectasis, cough, flu-like symptoms, pleural effusion, pneumothorax, pulmonary edema, respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever, postoperative pain, postoperative wound complication, wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Gastrointestinal: Gastroenteritis (2% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Adult respiratory distress syndrome, agranulocytosis, anaphylactoid reaction, anaphylaxis, angioedema, basal cell carcinoma, biliary tract disease (stenosis), blindness, cerebrovascular accident, coma, deafness, decreased serum fibrinogen, delirium, disseminated intravascular coagulation, dysarthria, graft versus host disease (acute and chronic), hemiparesis, hemolytic-uremic syndrome, hemorrhagic cystitis, hepatic cirrhosis, hepatic failure, hepatic necrosis, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatosplenic T-cell lymphomas, hepatotoxicity, hyperpigmentation, immune thrombocytopenia, interstitial pulmonary disease, leukemia, leukoencephalopathy, liver steatosis, lymphoproliferative disorder (post-transplant or related to Epstein-Barr virus), malignant lymphoma, malignant melanoma, multi-organ failure, mutism, optic atrophy, osteomyelitis, photophobia, polyarthritis, progressive multifocal leukoencephalopathy (PML), prolonged partial thromboplastin time, prolonged Q-T interval on ECG, pulmonary hypertension, pure red cell aplasia, quadriplegia, reversible posterior leukoencephalopathy syndrome, rhabdomyolysis, septicemia, squamous cell carcinoma, status epilepticus, Stevens-Johnson syndrome, supraventricular extrasystole, supraventricular tachycardia, thrombotic thrombocytopenic purpura, torsades de pointes, toxic epidermal necrolysis, urticaria, venous thrombosis, ventricular fibrillation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559526\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tacrolimus, polyoxyl 60 hydrogenated castor oil (HCO-60), or any other component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559527\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Injection: Hypersensitivity reactions, including anaphylaxis, have been reported with tacrolimus injection. Tacrolimus injection contains polyoxyl 60 hydrogenated castor oil (HCO-60), a castor oil derivative. HCO-60 is a solubilizer similar to polyoxyethylated castor oil (also known as polyoxyl 35 castor oil or Cremophor EL); polyoxyethylated castor oil is associated with hypersensitivity reactions (Nicolai 2012). Tacrolimus intravenous (IV) use should be limited to patients unable to take oral capsules. Monitor patient for a minimum of 30 minutes after initiation of infusion and then at frequent intervals; discontinue infusion if anaphylaxis occurs. Patients should be transitioned from IV to oral tacrolimus as soon as the patient can tolerate oral administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular: Myocardial hypertrophy has been reported; may be reversible with dose reduction or discontinuation. Prolongation of the QT/QTc and torsade de pointes may occur; avoid use in patients with congenital long QT syndrome. Consider obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus (post-transplant): The risk for new-onset diabetes and insulin-dependent post-transplant diabetes mellitus (PTDM) is increased with tacrolimus use after transplantation, including in patients without pretransplant history of diabetes mellitus. Insulin dependence may be reversible. Monitor blood glucose frequently. Risk is increased in African-American and Hispanic kidney transplant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal perforation: Gastrointestinal perforation may occur; all reported cases were considered to be a complication of transplant surgery or accompanied by infection, diverticulum, or malignant neoplasm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Mild-to-severe hyperkalemia may occur; monitor serum potassium levels and avoid use of potassium-sparing diuretics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Hypertension may commonly occur; antihypertensive treatment may be necessary; avoid use of potassium-sparing diuretics due to risk of hyperkalemia. Concurrent use of calcium channel blockers may require tacrolimus dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections:<b> [US Boxed Warning]: Immunosuppressant agents, including tacrolimus, increase the risk of infection; the risk of developing bacterial, viral (including CMV), fungal, and protozoal infections, including opportunistic infections, is increased.</b> Infections may result in serious and fatal outcomes. Latent viral infections may be activated, including BK virus (associated with polyoma virus-associated nephropathy [PVAN]) and JC virus (associated with progressive multifocal leukoencephalopathy [PML]); may result in serious adverse effects. Immunosuppression increases the risk for CMV viremia and/or CMV disease; the risk of CMV disease is increased for patients who are CMV-seronegative prior to transplant and receive a graft from a CMV-seropositive donor. Monitor for development of infection; consider reduction in immunosuppression if PVAN, PML, CMV viremia and/or CMV disease occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Immunosuppressant agents, including tacrolimus, may be associated with the development of lymphoma and other malignancies (predominantly skin malignancies).</b> The risk for malignancies is related to intensity/duration of therapy. Limit or avoid sun and ultraviolet light exposure; use appropriate sun protection. Post-transplant lymphoproliferative disorder related to EBV infection has been reported in immunosuppressed organ transplant patients; risk highest in young children; use combination immunosuppressant therapy with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Nephrotoxicity (acute or chronic) may occur when used in high doses, in patients with impaired renal function, with other nephrotoxic drugs (eg, sirolimus, cyclosporine), or when administered concomitantly with CYP3A inhibitors (due to increased tacrolimus concentrations). Monitor renal function and consider dosage reduction if nephrotoxicity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Neurotoxicity may occur especially when used in high doses; tremor, headache, coma, and delirium have been reported and are associated with serum concentrations. Seizures may also occur. Posterior reversible encephalopathy syndrome (PRES) has been reported; symptoms (altered mental status, headache, hypertension, seizures, and visual disturbances) are reversible with dose reduction or discontinuation of therapy; stabilize blood pressure and reduce dose with suspected or confirmed PRES diagnosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pure red cell aplasia (PRCA): PRCA has been reported in patients receiving tacrolimus. Use with caution in patients with risk factors for PRCA including parvovirus B19 infection, underlying disease, or use of concomitant medications associated with PRCA (eg, mycophenolate). Discontinuation of therapy should be considered with diagnosis of PRCA.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution; utilize lowest recommended IV or oral dose; additional dose reductions may be necessary; severe hepatic impairment (Child-Pugh score &ge;10) may require decreased dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Due to potential for further nephrotoxicity, utilize lowest recommended IV or oral dose; additional dose reductions may be necessary. Delay initiation of therapy in kidney transplant patients if postoperative oliguria occurs; begin therapy no sooner than 6 hours and within 24 hours post-transplant, but may be delayed until renal function has recovered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Concomitant use with strong CYP3A inducers and/or inhibitors may alter tacrolimus whole blood concentrations, potentially leading to rejection and/or increased toxicity, respectively. Monitor tacrolimus whole blood trough concentrations closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Everolimus combination therapy: In liver transplantation, the tacrolimus dose and target range should be reduced to minimize the risk of nephrotoxicity when used in combination with everolimus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sirolimus combination therapy: Extended release tacrolimus in combination with sirolimus is not recommended in renal transplant patients; the safety and efficacy of immediate release tacrolimus in combination with sirolimus has not been established in this patient population. Concomitant use was associated with increased mortality, graft loss, and hepatic artery thrombosis in liver transplant patients, as well as increased risk of renal impairment, wound healing complications, and PTDM in heart transplant recipients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended release: <b>[US Boxed Warning]: Astagraf XL was associated with increased mortality in female liver transplant recipients; the use of extended release tacrolimus is not approved for use in liver transplantation.</b> Mortality at 12 months was 10% higher in females who received extended release tacrolimus compared to females who received regular release tacrolimus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Each mL of injection contains polyoxyl 60 hydrogenated castor oil (HCO-60) (200 mg) and dehydrated alcohol USP 80% v/v. Anaphylaxis has been reported with the injection, use should be reserved for those patients not able to take oral medications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Oral formulations contain lactose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Error prevention: Immediate release and extended release capsules are <b>NOT</b> interchangeable or substitutable. The extended release formulation is a once-daily preparation; and immediate release formulation is intended for twice-daily administration. Serious adverse events, including organ rejection, may occur if inadvertently substituted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppressive therapy and organ transplantation in a facility appropriate for monitoring and managing therapy.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Patients should not be immunized with live vaccines during or shortly after treatment and should avoid close contact with recently vaccinated (live vaccine) individuals. Inactivated vaccines may be administered (response may be diminished).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monitoring of concentrations: Closely monitor tacrolimus levels to assist in dose adjustment, monitor compliance, prevent organ rejection, and reduce drug-related toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564168\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564169\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9920&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: Tacrolimus (Systemic) may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10 mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer tacrolimus simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May increase the absorption of Tacrolimus (Systemic). More specifically, the initial absorption rate may be increased, as alcohol may speed the release of tacrolimus from extended-release tablets. Management: Advise patients receiving extended-release tacrolimus (Astagraf XL or Envarsus XR brands) not to take the medication with alcoholic beverages.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of Tacrolimus (Systemic). Specifically, this increase in tacrolimus concentrations may occur during the first week of combined therapy. Asunaprevir may decrease the serum concentration of Tacrolimus (Systemic). Specifically, this decrease in tacrolimus concentrations may occur with continued prolonged combination therapy.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azithromycin (Systemic): May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus doses will need to be substantially reduced, and the tacrolimus dosing interval will likely need to be prolonged with concurrent boceprevir. Follow tacrolimus concentrations closely and monitor patients for evidence of tacrolimus toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Dihydropyridine): May increase the serum concentration of Tacrolimus (Systemic).<b> Exceptions: </b>Clevidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Tacrolimus (Systemic).<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caspofungin: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of chloramphenicol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cinacalcet: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clotrimazole (Oral): May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clotrimazole (Topical): May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: Tacrolimus (Systemic) may increase the serum concentration of Colchicine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the nephrotoxic effect of Tacrolimus (Systemic). Tacrolimus (Systemic) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Tacrolimus (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tacrolimus (Systemic). Management: Monitor clinical tacrolimus response closely and frequently monitor tacrolimus serum concentrations with concurrent use of any strong CYP3A4 inhibitor.  Tacrolimus dose reductions and/or prolongation of the dosing interval will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May decrease the serum concentration of Tacrolimus (Systemic). Specifically, this decrease in tacrolimus concentrations may occur with continued prolonged combination therapy. Daclatasvir may increase the serum concentration of Tacrolimus (Systemic). Specifically, this increase in tacrolimus concentrations may occur during the first week of combined therapy.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: Tacrolimus (Systemic) may enhance the QTc-prolonging effect of Dronedarone. Dronedarone may increase the serum concentration of Tacrolimus (Systemic).  Management: Monitor for increased serum tacrolimus concentrations, tacrolimus toxicity, and QTc interval prolongation if combined with dronedarone. Tacrolimus dose adjustments may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Tacrolimus (Systemic). Management: Closely monitor tacrolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of tacrolimus may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efonidipine: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ertapenem: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenofibrate and Derivatives: Tacrolimus (Systemic) may enhance the nephrotoxic effect of Fenofibrate and Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: Monitor tacrolimus concentrations closely and adjust oral tacrolimus dose as necessary when concomitantly administered with fluconazole.  Reduced doses of tacrolimus will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May decrease the metabolism of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with itraconazole. Tacrolimus dose reductions will likely be required. The magnitude of this interaction may be greater in older patients.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose adjustment may be required when taken with ketoconazole due to elevated plasma concentrations of tacrolimus.  Monitor tacrolimus concentrations and clinical response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LevoFLOXacin (Systemic): May enhance the QTc-prolonging effect of Tacrolimus (Systemic). LevoFLOXacin (Systemic) may increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Tacrolimus (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of Tacrolimus (Systemic). MiFEPRIStone may increase the serum concentration of Tacrolimus (Systemic). Management: Avoid tacrolimus during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: Reduce tacrolimus dose to approximately one-third of original dose when starting posaconazole. Tacrolimus blood concentrations should be monitored closely during and at discontinuation of posaconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May decrease the metabolism of Tacrolimus (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.<b> Exceptions: </b>Pantoprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Tacrolimus (Systemic). Management: Consider alternatives when possible.  If these combination are used, monitor for reduced tacrolimus concentrations/effects following rifamycin initiation/dose increase, or increased concentrations/effects following rifamycin discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose reductions may be needed with concurrent ritonavir. Monitor tacrolimus concentrations closely to determine dose; doses of tacrolimus 0.5 mg to 1 mg every week may be adequate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Schisandra: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Reuptake Inhibitor/Antagonists: May decrease the metabolism of Tacrolimus (Systemic).<b> Exceptions: </b>TraZODone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: May enhance the adverse/toxic effect of Tacrolimus (Systemic). Tacrolimus (Systemic) may enhance the adverse/toxic effect of Sirolimus. Sirolimus may decrease the serum concentration of Tacrolimus (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Tacrolimus (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Tacrolimus (Systemic). Management: Significant tacrolimus dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both tacrolimus concentrations and clinical response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Tacrolimus (Systemic) may enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Systemic). Temsirolimus may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofisopam: May increase the serum concentration of Tacrolimus (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Tacrolimus (Systemic). Management: When starting voriconazole in patients already receiving tacrolimus, reduce tacrolimus dose to one-third of the original dose. Monitor tacrolimus blood levels closely.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564173\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ethanol: Alcohol may increase the rate of release of extended-release tacrolimus and adversely affect tacrolimus safety and/or efficacy. Management: Avoid alcohol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Food: Food decreases rate and extent of absorption. High-fat meals have most pronounced effect (37% and 25% decrease in AUC, respectively, and 77% and 25%  decrease in C<sub>max</sub>, respectively, for immediately release and extended release formulations). Grapefruit juice, a CYP3A4 inhibitor, may increase serum level and/or toxicity of tacrolimus. Management: Administer with or without food (immediate release), but be consistent. Administer extended release on an empty stomach. Avoid concurrent use of grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559521\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559522\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Tacrolimus crosses the human placenta and is measurable in the cord blood, amniotic fluid, and newborn serum. Tacrolimus concentrations in the placenta may be higher than the maternal serum (Jain 1997). Infants with lower birth weights have been found to have higher tacrolimus concentrations (Bramham 2013). Transient neonatal hyperkalemia and renal dysfunction have been reported.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Tacrolimus pharmacokinetics are altered during pregnancy. Whole blood concentrations decrease as pregnancy progresses; however, unbound concentrations increase. Measuring unbound concentrations may be preferred, especially in women with anemia or hypoalbuminemia. If unbound concentration measurement is not available, interpretation of whole blood concentrations should account for RBC count and serum albumin concentration (Hebert 2013; Zheng 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, women who have had a kidney transplant should be instructed that fertility will be restored following the transplant but that pregnancy should be avoided for ~2 years. Tacrolimus may be used as an immunosuppressant during pregnancy. The risk of infection, hypertension, and pre-eclampsia may be increased in pregnant women who have had a kidney transplant (EPBG 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9559525\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tacrolimus is excreted into breast milk; concentrations are variable and lower than that of the maternal serum. The low bioavailability of tacrolimus following oral absorption may also decrease the amount of exposure to a nursing infant (Bramham 2013; French 2003; Gardiner 2006). In one study, tacrolimus serum concentrations in the infants did not differ between those who were bottle fed or breast-fed (all infants were exposed to tacrolimus throughout pregnancy) (Bramham 2013). Available information suggests that tacrolimus exposure to the nursing infant is &le;0.5% of the weight-adjusted maternal dose (Bramham 2013; French 2003; Gardiner 2006). The manufacturer recommends that nursing be discontinued, taking into consideration the importance of the drug to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564222\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Capsule: Administer immediate release with or without food; be consistent with timing and composition of meals, food decreases bioavailability. Administer extended release on an empty stomach 1 hour before or 2 hours after a meal. Avoid grapefruit and grapefruit juice. Avoid alcohol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564239\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function, hepatic function, serum electrolytes (magnesium, phosphorus, potassium), glucose and blood pressure, measure 3 times/week for first few weeks, then gradually decrease frequency as patient stabilizes. Signs/symptoms of anaphylactic reactions during IV infusion should also be monitored. Patients should be monitored for hypersensitivity during the first 30 minutes of the infusion, and frequently thereafter. Monitor for QT prolongation; consider echocardiographic evaluation in patients who develop renal failure, electrolyte abnormalities, or clinical manifestations of ventricular dysfunction.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Whole blood concentrations should be used for monitoring (trough for oral therapy drawn typically within 30 minutes prior to the next dose); frequency varies depending on transplant type, time since transplantation, and clinical situation. Tacrolimus serum levels may be falsely elevated in infected liver transplant patients due to interference from beta-galactosidase antibodies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564191\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In solid organ transplant recipients, goal levels vary depending on patient risk factors, concomitant immunosuppression, and time post-transplant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heart transplant: Typical whole blood trough concentrations (in combination with azathioprine or mycophenolate), goal levels may vary in patients on mTOR inhibitors and goal levels for this combination have not been adequately determined (ISHLT [Costanzo 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Days 0 to 60: 10 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Months 3 to 6: 8 to 12 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;6 months: 5 to 10 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kidney transplant: Whole blood trough concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In combination with azathioprine (if used):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Months 1 to 3: 7 to 20 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Months 4 to 12: 5 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In combination with mycophenolate mofetil/IL-2 receptor antagonist (eg, basiliximab): 4 to 11 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In combination with mTOR inhibitor (everolimus): 4 to 8 ng/mL for the first 2 months post-transplant followed by 3 to 5 ng/mL thereafter (Sommerer 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (Astagraf XL):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">With basiliximab induction:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Month 1: 7 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Months 2 to 6: 5 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;6 months: 5 to 10 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Without induction:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Month 1: 10 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Months 2 to 6: 5 to 15 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;6 months: 5 to 10 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (Envarsus XR): 4 to 11 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liver transplant: Whole blood trough concentrations: Months 1 to 12: 5 to 20 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Recommended therapeutic ranges when administered in combination with everolimus for liver transplant (Zortress product labeling 2013):</i> By 3 weeks after first everolimus dose and through month 12 post-transplant: 3 to 5 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intestinal transplant (off-label use): Months 1 to 3: 10 to 20 ng/mL followed by gradual dose reduction; concentrations allowed to decrease over the first year so that by 12 months trough levels range from 5 to 10 ng/mL (Abu-Elmagd 2009; Horslen 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lung transplant (off-label use): Whole blood trough concentrations: 5 to 15 ng/mL (ACCP [Baughman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of graft-versus-host disease (off-label use): Whole blood trough concentrations: 10 to 20 ng/mL (Uberti 1999) although some institutions use a lower limit of 5 ng/mL and an upper limit of 15 ng/mL (Przepiorka 1999; Yanik 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564189\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Suppresses cellular immunity (inhibits T-lymphocyte activation), by binding to an intracellular protein, FKBP-12 and complexes with calcineurin dependent proteins to inhibit calcineurin phosphatase activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564197\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Better in resected patients with a closed stoma; unlike cyclosporine, clamping of the T-tube in liver transplant patients does not alter trough concentrations or AUC; Oral: Incomplete and variable (5% to 67%); the rate and extent of absorption is decreased (27%) by food (particularly a high-fat meal). Oral absorption may be variable in stem cell transplant patients with mucositis due to the conditioning regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes to erythrocytes, lung, kidneys, pancreas, liver, heart, and spleen;  V<sub>d</sub>: Children: 2.6 L/kg (mean) ; Adults: 0.85 to 1.41 L/kg (mean) in liver and renal transplant patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~99% primarily to albumin and alpha-1 acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via CYP3A4 to eight possible metabolites (major metabolite, 31-demethyl tacrolimus, shows same activity as tacrolimus in vitro)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Children: 7% to 55%, Adults: 7% to 32%; Absolute: Unknown</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 7.7 to 15.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate release: Variable, 23 to 46 hours in healthy volunteers; 2.1 to 36 hours in transplant patients; prolonged in patients with severe impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Extended release: 38 &plusmn; 3 hours; prolonged in patients with severe hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 0.5 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~93%); urine (&lt;1% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: 7 to 103 mL/minute/kg (average: 30 mL/minute/kg); clearance higher in children</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9564279\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Astagraf XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (30): $84.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $169.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $847.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Prograf Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $358.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $716.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $3,583.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tacrolimus Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $222.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $445.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $2,229.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Prograf Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (1 mL): $247.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Envarsus XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 mg (30): $130.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $174.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $698.39</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390236\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adoport (GB);</li>\n      <li>Advagraf (BE, CN, CZ, DE, DK, EE, ES, FR, GB, HK, HR, IE, IS, LT, LU, LV, MT, NO, PH, QA, RO, SE, SI, SK, TH, TR, TW, VN);</li>\n      <li>Advahraf (UA);</li>\n      <li>Capexion (GB);</li>\n      <li>Cidimus (PH);</li>\n      <li>Envarsus (AT, CZ, DE, DK, EE, ES, FR, GB, GR, HR, HU, IE, LT, LV, NL, NO, PL, PT, SI);</li>\n      <li>Graceptor (JP);</li>\n      <li>Modigraf (GB, IE, LV);</li>\n      <li>Pangraf (IN, LK);</li>\n      <li>Panraf (JO);</li>\n      <li>Prograf (AE, AR, AT, AU, BB, BE, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, ID, IE, IL, IQ, IR, IS, IT, JO, JP, KR, KW, LB, LY, MT, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TH, TR, TW, UY, VE, VN, YE);</li>\n      <li>Prograf XL (AU, CO);</li>\n      <li>Prograft (LU);</li>\n      <li>Prohraf (UA);</li>\n      <li>Regraf (LK);</li>\n      <li>T-Inmun (PY);</li>\n      <li>Tacgraf (LK);</li>\n      <li>Tacrobell (KR);</li>\n      <li>Tacrotec (PH);</li>\n      <li>Tagraf (PH);</li>\n      <li>Tarimus (KR);</li>\n      <li>Vingraf (LK, PH);</li>\n      <li>Vivadex (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18954362\"></a>Abu-Elmagd KM, Costa G, Bond GJ, et al. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. <i>Transpl Int</i>. 2009;22(1):96-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/18954362/pubmed\" target=\"_blank\" id=\"18954362\">18954362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19730240\"></a>Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. <i>Ann Surg</i>. 2009;250(4):567-581.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/19730240/pubmed\" target=\"_blank\" id=\"19730240\">19730240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Advagraf (tacrolimus) [product monograph]. Markham, ON, Canada: Astellas Pharma Canada Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Afshar K. Future direction of immunosuppression in lung transplantation. <i>Curr Opin Organ Transplant</i>. 2014;19(6):583-590.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/25260152/pubmed\" target=\"_blank\" id=\"25260152\">25260152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asante-Korang A, Boyle GJ, Webber SA, et al, &ldquo;Experience of FK506 Immune Suppression in Pediatric Heart Transplantation: A Study of Long-Term Adverse Effects,&rdquo; <i>J Heart Lung Transplant</i>, 1996, 15(4):415-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/8732602/pubmed\" target=\"_blank\" id=\"8732602\">8732602</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Astagraf XL (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atkison P, Joubert G, Barron A, et al, &ldquo;Hypertrophic Cardiomyopathy Associated With Tacrolimus in Paediatric Transplant Patients,&rdquo; <i>Lancet</i>, 1995, 345(8954):894-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/7535875/pubmed\" target=\"_blank\" id=\"7535875\">7535875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baughman RP, Meyer KC, Nathanson I, et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;142(5):e1S-e111S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/23131960/pubmed\" target=\"_blank\" id=\"23131960\">23131960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bramham K, Chusney G, Lee J, et al, &quot;Breastfeeding and Tacrolimus: Serial Monitoring in Breast-Fed and Bottle-Fed Infants,&quot; <i>Clin J Am Soc Nephrol</i>, 2013, Apr;8(4):563-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/23349333/pubmed\" target=\"_blank\" id=\"23349333\">23349333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Collin C, Boussaud V, Lefeuvre S, et al. Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. <i>Transplant Proc. </i>2010;42(10):4331-4337.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/21168693/pubmed\" target=\"_blank\" id=\"21168693\">21168693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doligalski CT, Liu EC, Sammons CM, Silverman A, Logan AT. Sublingual administration of tacrolimus: current trends and available evidence. <i>Pharmacotherapy</i>. 2014;34(11):1209-1219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/25251980/pubmed\" target=\"_blank\" id=\"25251980\">25251980</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EBPG Expert Group on Renal Transplantation, &quot;European Best Practice Guidelines For Renal Transplantation. Section IV: Long-Term Management of the Transplant Recipient, IV.10. Pregnancy in Renal Transplant Recipients,&quot; <i>Nephrol Dial Transplant</i>, 2002, 17 Suppl 4:50-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/12091650/pubmed\" target=\"_blank\" id=\"12091650\">12091650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elefante A, Muindi J, West K, et al, &ldquo;Long-Term Stability of a Patient-Convenient 1 mg/mL Suspension of Tacrolimus for Accurate Maintenance of Stable Therapeutic Levels,&rdquo; <i>Bone Marrow Transplant</i>, 2006, 37(8):781-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/16518428/pubmed\" target=\"_blank\" id=\"16518428\">16518428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Esquivel C, So S, McDiarmid S, Andrews W, and Colombani PM, &ldquo;Suggested Guidelines for the Use of Tacrolimus in Pediatric Liver Transplant Patients,&rdquo; <i>Transplantation</i>, 1996, 61(5):847-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/8607198/pubmed\" target=\"_blank\" id=\"8607198\">8607198</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Envarsus XR (tacrolimus) [prescribing information]. Edison, NJ: Veloxis Pharmaceuticals; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foster JA, Jacobson PA, Johnson CE, et al, &ldquo;Stability of Tacrolimus in an Extemporaneously Compounded Oral Liquid (Abstract of Meeting Presentation),&rdquo; <i>American Society of Health-System Pharmacists Annual Meeting</i>, 1996, 53:P-52(E).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/9117806/pubmed\" target=\"_blank\" id=\"9117806\">9117806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French AE, Soldin SJ, Soldin OP, et al, &ldquo;Milk Transfer and Neonatal Safety of Tacrolimus,&rdquo; <i>Ann Pharmacother</i>, 2003, 37(6):815-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/12773068/pubmed\" target=\"_blank\" id=\"12773068\">12773068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24932812\"></a>Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus. <i>Transpl Immunol</i>. 2014;31(2):87-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/24932812/pubmed\" target=\"_blank\" id=\"24932812\">24932812</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furlan V, Perello L, Jacquemin E, et al, &ldquo;Interactions Between FK506 and Rifampicin or Erythromycin in Pediatric Liver Recipients,&rdquo; <i>Transplantation</i>, 1995, 59(8):1217-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/7537398/pubmed\" target=\"_blank\" id=\"7537398\">7537398</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11100278\"></a>Furlong T, Storb R, Anasetti C, et al, &ldquo;Clinical Outcome After Conversion to FK 506 (Tacrolimus) Therapy for Acute Graft-Versus-Host Disease Resistant to Cyclosporine or for Cyclosporine-Associated Toxicities,&rdquo; <i>Bone Marrow Transplant</i>, 2000, 26(9):985-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/11100278/pubmed\" target=\"_blank\" id=\"11100278\">11100278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardiner SJ and Begg EJ, &ldquo;Breastfeeding During Tacrolimus Therapy,&rdquo; <i>Obstet Gynecol</i>, 2006, 107(2 Pt 2):453-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/16449146/pubmed\" target=\"_blank\" id=\"16449146\">16449146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garrity ER Jr, Hertz MI, Trulock EP, Keenan R, Love R. Suggested guidelines for the use of tacrolimus in lung-transplant recipients. <i>J Heart Lung Transplant</i>. 1999;18(3):175-176.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/10328140/pubmed\" target=\"_blank\" id=\"10328140\">10328140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25701373\"></a>Guethoff S, Stroeh K, Grinninger C, et al. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results. <i>J Heart Lung Transplant</i>. 2015;34(5):634-642.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/25701373/pubmed\" target=\"_blank\" id=\"25701373\">25701373</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grimer M and Caring for Australians with Renal Impairment (CARI), &ldquo;The CARI Guidelines. Calcineurin Inhibitors in Renal Transplantation: Pregnancy, Lactation and Calcineurin Inhibitors,&rdquo; Nephrology (Carlton), 2007, 12(Suppl 1):98-105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/17316288/pubmed\" target=\"_blank\" id=\"17316288\">17316288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hachem RR, Yusen RD, Chakinala MM, Meyers BF, Lynch JP, Aloush AA, Patterson GA, Trulock EP. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. <i>J Heart Lung Transplant</i>. 2007 Oct;26(10):1012-1018.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/17919621/pubmed\" target=\"_blank\" id=\"17919621\">17919621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hebert MF, Zheng S, Hays K, et al, &quot;Interpreting Tacrolimus Concentrations During Pregnancy and Postpartum,&quot; <i>Transplantation</i>, 2013, 95(7):908-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/23274970/pubmed\" target=\"_blank\" id=\"23274970\">23274970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hecoria (tacrolimus) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hodak SP, Moubarak JB, Rodriguez I, et al, &ldquo;QT Prolongation and Near Fatal Cardiac Arrhythmia After Intravenous Tacrolimus Administration: A Case Report,&rdquo; <i>Transplantation</i>, 1998, 66(4):535-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/9734501/pubmed\" target=\"_blank\" id=\"9734501\">9734501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16473067\"></a>Horslen SP. Optimal management of the post-intestinal transplant patient. <i>Gastroenterology</i>. 2006;130(2 Suppl 1):S163-169.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/16473067/pubmed\" target=\"_blank\" id=\"16473067\">16473067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15919450\"></a>Iwahori T, Takeuchi H, Matsuno N, et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. <i>Transplant Proc</i>. 2005;37(4):1739-1740.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/15919450/pubmed\" target=\"_blank\" id=\"15919450\">15919450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jain A, Venkataramanan R, Fung JJ, et al, &ldquo;Pregnancy After Liver Transplantation Under Tacrolimus,&rdquo; <i>Transplantation</i>, 1997, 64(4):559-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/9293865/pubmed\" target=\"_blank\" id=\"9293865\">9293865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson MC, So S, March JW, et al, &ldquo;QT Prolongation and Torsades de Pointes After Administration of FK506,&rdquo; <i>Transplantation</i>, 1992, 53(4):929-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/1373538/pubmed\" target=\"_blank\" id=\"1373538\">1373538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jusko WJ, Piekoszewski W, Klintmalm GB, et al, &ldquo;Pharmacokinetics of Tacrolimus in Liver Transplant Patients,&rdquo; <i>Clin Pharmacol Ther</i>, 1995, 57(3):281-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/7535213/pubmed\" target=\"_blank\" id=\"7535213\">7535213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kainz A, Harabacz I, Cowlrick IS, et al, &ldquo;Analysis of 100 Pregnancy Outcomes in Women Treated Systemically With Tacrolimus,&rdquo; <i>Transpl Int</i>, 2000, 13(Suppl 1):299-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/11112018/pubmed\" target=\"_blank\" id=\"11112018\">11112018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaufman DB, Kaplan B, Kanwar YS, et al, &ldquo;The Successful Use of Tacrolimus (FK506) in a Pancreas/Kidney Transplant Recipient With Recurrent Cyclosporine-Associated Hemolytic Uremic Syndrome,&rdquo; <i>Transplantation</i>, 1995, 59(12):1737-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/7541579/pubmed\" target=\"_blank\" id=\"7541579\">7541579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly PA, Burckart GJ, and Venkataramanan R, &ldquo;Tacrolimus: A New Immunosuppressive Agent,&rdquo; <i>Am J Health Syst Pharm</i>, 1995, 52(14):1521-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/7552894/pubmed\" target=\"_blank\" id=\"7552894\">7552894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knorr JP, Grewal KS, Balasubramanian M, et al, &ldquo;Falsely Elevated Tacrolimus Levels Caused by Immunoassay Interference Secondary to Beta-Galactosidase Antibodies in an Infected Liver Transplant Recipient,&rdquo; <i>Pharmacotherapy</i>, 2010, 30(9):954.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/20812435/pubmed\" target=\"_blank\" id=\"20812435\">20812435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26961485\"></a>Lee WS, Lee SI, Lee MS, Kim SI, Lee SS, Yoo WH. Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate. <i>Korean J Intern Med</i>. 2016;31(4):779-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/26961485/pubmed\" target=\"_blank\" id=\"26961485\">26961485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacDonald AS and Sketris IS, &ldquo;Tacrolimus in Transplantation,&rdquo; <i>Am J Health Syst Pharm</i>, 1995, 52(14):1569-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/7552906/pubmed\" target=\"_blank\" id=\"7552906\">7552906</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDiarmid SV, Colonna JO, Shaked A, et al, &ldquo;Differences in Oral FK506 Dose Requirements Between Adults and Pediatric Liver Transplant Patients,&rdquo; <i>Transplantation</i>, 1993, 55(6):1328-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/7685933/pubmed\" target=\"_blank\" id=\"7685933\">7685933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&eacute;ndez A, Berastegui C, L&oacute;pez-Meseguer M, Monforte V, Bravo C, Blanco A, Cam&oacute;s S, Pou L, Roman A. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. <i>Transplantation</i>. 2014;97(3):358-362.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/24492423/pubmed\" target=\"_blank\" id=\"24492423\">24492423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menegaux F, Keeffe EB, Andrews BT, et al, &ldquo;Neurological Complications of Liver Transplantation in Adult Versus Pediatric Patients,&rdquo; <i>Transplantation</i>, 1994, 58(4):447-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/8073514/pubmed\" target=\"_blank\" id=\"8073514\">8073514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25359357\"></a>Meyer KC, Raqhu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44(6):1479-1503.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/25359357/pubmed\" target=\"_blank\" id=\"25359357\">25359357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Messina C, Faraci M, de Fazio V, et al, &ldquo;Paediatric Working Party. Prevention and Treatment of Acute GvHD,&rdquo; <i>Bone Marrow Transplant</i>, 2008, 41(Suppl 2):65-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/18545247/pubmed\" target=\"_blank\" id=\"18545247\">18545247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9165550\"></a>Min DI, Chen HY, Lee MK, Ashton K, Martin MF. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. <i>Pharmacotherapy</i>. 1997;17(3):457-463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/9165550/pubmed\" target=\"_blank\" id=\"9165550\">9165550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nasiri-Toosi Z, Dashti-Khavidaki S, Nasiri-Toosi M, et al. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. <i>Exp Clin Transplant. </i>2012;10(6):586-591.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/22770208/pubmed\" target=\"_blank\" id=\"22770208\">22770208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Natazuka T, Ogawa R, Kizaki T, et al, &ldquo;Immunosuppressive Drugs and Hypertrophic Cardiomyopathy,&rdquo; <i>Lancet</i>, 1995, 345(8965):1644.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/7540241/pubmed\" target=\"_blank\" id=\"7540241\">7540241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolai S and Bunyavanich S. Hypersensitivity reaction to intravenous but not oral tacrolimus. <i>Transplantation</i>. 2012;94(9):e61-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/23128975/pubmed\" target=\"_blank\" id=\"23128975\">23128975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17391292\"></a>Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Tedesco-Silva H Jr, Medina-Pestana JO. Circadian and time-dependent variability in tacrolimus pharmacokinetics. <i>Fundam Clin Pharmacol</i>. 2007;21(2):191-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/17391292/pubmed\" target=\"_blank\" id=\"17391292\">17391292</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23932018\"></a>Peddi VR, Wiseman A, Chavin K, Slakey D. Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev (Orlando). 2013;27(4):97-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/23932018/pubmed\" target=\"_blank\" id=\"23932018\">23932018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Penninga L, Penninga EI, M&oslash;ller CH, Iversen M, Steinbr&uuml;chel DA, Gluud C. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. <i>Cochrane Database Syst Rev</i>. 2013;5:CD008817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/23728681/pubmed\" target=\"_blank\" id=\"23728681\">23728681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Podesser BK, Rinaldi M, Yona NA, et al, &ldquo;Comparison of Low and High Initial Tacrolimus Dosing in Primary Heart Transplant Recipients: A Prospective European Multicenter Study,&rdquo; <i>Transplantation</i>, 2005, 79(1):65-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/15714171/pubmed\" target=\"_blank\" id=\"15714171\">15714171</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prograf (tacrolimus) [product monograph]. Markham, ON, Canada: Astellas Pharma Canada Inc; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10578154\"></a>Przepiorka D, Devine S, Fay J, et al, &ldquo;Practical Considerations in the Use of Tacrolimus for Allogeneic Marrow Transplantation,&rdquo; <i>Bone Marrow Transplant</i>, 1999, 24(10):1053-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/10578154/pubmed\" target=\"_blank\" id=\"10578154\">10578154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Przepiorka D, Suzuki J, Ippoliti C, et al, &ldquo;Blood Tacrolimus Concentration Unchanged by Plasmapheresis,&rdquo; <i>Am J Hosp Pharm</i>, 1994, 51(13):1708.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/7524318/pubmed\" target=\"_blank\" id=\"7524318\">7524318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reams BD, Palmer SM. Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis. <i>Am J Respir Med. </i>2002;1(2):91-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/14720063/pubmed\" target=\"_blank\" id=\"14720063\">14720063</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Snell GI, Westall GP, Paraskeva MA. Immunosuppression and allograft rejection following lung transplantation: evidence to date. <i>Drugs</i>. 2013;73(16):1793-1813.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/24142409/pubmed\" target=\"_blank\" id=\"24142409\">24142409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26888217\"></a>Sommerer C, Suwelack B, Draqun D, et al. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. <i>Trials</i>. 2016;17:92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/26888217/pubmed\" target=\"_blank\" id=\"26888217\">26888217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starzl TE, Fung J, Jordan M, et al, &ldquo;Kidney Transplantation Under FK506,&rdquo; <i>JAMA</i>, 1990, 264(1):63-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/1693970/pubmed\" target=\"_blank\" id=\"1693970\">1693970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor DO, Barr ML, Meiser BM, Pham SM, Mentzer RM, Gass AL. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. <i>J Heart Lung Transplant</i>. 2001;20(7):734-738.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/11448799/pubmed\" target=\"_blank\" id=\"11448799\">11448799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treede H, Glanville AR, Klepetko W, et al; European and Australian Investigators in Lung Transplantation. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. <i>J Heart Lung Transplant</i>. 2012;31(8):797-804.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/22554673/pubmed\" target=\"_blank\" id=\"22554673\">22554673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treede H, Klepetko W, Reichenspurner H, et al; Munich and Vienna Lung Transplant Group. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. <i>J Heart Lung Transplant</i>. 2001;20(5):511-517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/11343977/pubmed\" target=\"_blank\" id=\"11343977\">11343977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27340950\"></a>Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study.<i> Am J Transplant</i>. 2017;17(2):434-442.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/27340950/pubmed\" target=\"_blank\" id=\"27340950\">27340950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18031144\"></a>Uberti JP, Cronin S, and Ratanatharathorn V, &ldquo;Optimum Use of Tacrolimus in the Prophylaxis of Graft Versus Host Disease,&rdquo; <i>BioDrugs</i>, 1999, 11(5):343-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/18031144/pubmed\" target=\"_blank\" id=\"18031144\">18031144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Hooff J, Van der Walt I, Kallmeyer J, et al. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. <i>Ther Drug Monit</i>. 2012;34(1):46-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/22249344/pubmed\" target=\"_blank\" id=\"22249344\">22249344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watkins KD, Boettger RF, Hanger KM, et al. Use of sublingual tacrolimus in lung transplant recipients. <i>J Heart Lung Transplant</i>. 2012;31(2):127-132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/22177691/pubmed\" target=\"_blank\" id=\"22177691\">22177691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winkel E, DiSesa VJ, and Costanzo MR, &ldquo;Advances in Heart Transplantation,&rdquo; <i>Dis Mon</i>, 1999, 45(3):62-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/10080968/pubmed\" target=\"_blank\" id=\"10080968\">10080968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Witt CA, Hachem RR. Immunosuppression: what's standard and what's new? <i>Semin Respir Crit Care Med</i>. 2013;34(3):405-413.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/23821513/pubmed\" target=\"_blank\" id=\"23821513\">23821513</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yanik G, Levine JE, Ratanatharathorn V, et al, &ldquo;Tacrolimus (FK506) and Methotrexate as Prophylaxis for Acute Graft-Versus-Host Disease in Pediatric Allogeneic Stem Cell Transplantation,&rdquo; <i>Bone Marrow Transplant</i>, 2000, 26(2):161-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/10918426/pubmed\" target=\"_blank\" id=\"10918426\">10918426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14673984\"></a>Yocum DE, Furst DE, Kaine JL, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. <i>Arthritis Rheum</i>. 2003;48(12):3328-3337.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/14673984/pubmed\" target=\"_blank\" id=\"14673984\">14673984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zheng S, Easterling TR, Umans JG, et al, &quot;Pharmacokinetics of Tacrolimus During Pregnancy,&quot; <i>Ther Drug Monit</i>, 2012, 34(6):660-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/23007747/pubmed\" target=\"_blank\" id=\"23007747\">23007747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. <i>J Thorac Cardiovasc Surg</i>. 2003;125(4):891-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tacrolimus-systemic-drug-information/abstract-text/12698153/pubmed\" target=\"_blank\" id=\"12698153\">12698153</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9920 Version 232.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9559505\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9559510\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9559511\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9564525\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9564218\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9564217\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9564219\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9564220\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9564221\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9564277\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9559517\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F29038337\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F13262301\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50136484\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F21099222\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9564223\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133425\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9559518\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744916\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9559508\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9559542\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9559526\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9559527\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9564168\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9564169\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F9564173\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9559521\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9559522\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9559525\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9564222\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9564239\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F9564191\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9564189\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9564197\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9564279\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390236\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9920|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tacrolimus-systemic-patient-drug-information\" class=\"drug drug_patient\">Tacrolimus (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=tacrolimus-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Tacrolimus (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}